TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Lymphoma, Non-Hodgkin
• Multiple Myeloma
• Advanced Solid Tumors

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

12 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

American Society of Clinical Oncology

Last updated on ClinicalTrials.gov

September 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites